buy Pregabalin uk In a volatile sell-off day involving tech stocks, the biotech world was relatively calm. Despite good news on corporate earnings and a GDP with an annual 5.7% annual growth, investors chose to take profits even on solid player like Microsoft down over 3% today. Market Strength is routinely being sold. Biotech stocks stayed out of […]
go site Large Cap biomedical stocks held firm on another volatile but down day in the market driven by a host of macro and fundamental factors: earnings, Davos, Greece,China, politics, Bernanke confirmation, strong dollar, jobs, etc. In this convoluted market the technology leader Apple ( PE 26.6,EPS $7.49) with their iPad launch does not threaten Amazon’s (PE […]
follow link Gilead (GILD) shares were up 6% to $47.75 after the close as the Company announced record sales and earnings. Full Year total Revenues were $7.01B up 31% over 2008. Full Year Non-GAAP EPS were $3.06 up 40% over 2008. Fourth Quarter Non-GAAP EPS were $0.93 up 49% over 2008. Average analysts revenue estimates for 2010 […]
AMGN-Top line revenue slowing One of the largest biotech companies reported earnings within estimates with full year 2009 EPS of $4.91 up 8% on Revenue of $14.6B down 2%.2010 Total Revenue is expected to be in the $15.1B to $15.5B range with adjusted EPS at $5.05 to $5.25.U.S. Product Sales were $11.13B a decrease of […]
It is hard to believe but the Obama administration wants to open up a new political front at the last minute to squeeze the biotechnology industry after everyone thought the 12 year protection from generic biologicals was a “done deal”. http://www.genengnews.com/articles/chitem.aspx?aid=2717 Last-ditch lobbying battle over biotech drugs By ALAN FRAM The Associated Press Thursday, January […]
Here are some of the broader themes and market trends gleaned from Company presentations: 1.) There is a shift from small molecule drug development to biologicals and vaccines. e.g. Pfizer (PFE) 2.) “Bolt-on” acquisitions of smaller companies are being done to bolster product portfolios and emerging market positions. e.g. GSK 3.) There is increasing synergy […]
Over 5000 people piled into the Westin St. Francis Hotel in San Francisco for the 28th Annual Conference. Investors, Company presenters and entrepreneurs were emboldened by good biotech sector returns in 2009 of 18-28% with many stocks reaching new highs. Seasonality has been a factor with the so-called “January effect” where small cap stocks tend […]
We will be attending the 28th Annual JPMorgan Healthcare Conference in San Francisco and reporting on various companies and news on the Genetic Engineering News WEB site (www.genengnews.com). Although we will be attending presentations of companies in all sectors we will try to focus on the following: Diagnostics e.g, GenProbe, Idexx, Inverness Genomics e.g. Celera, […]
Robert W. Baird and Co. analyst Lawrence Neibor upgraded four medtech stocks and helped get the “January effect” in full swing. Cyberonics (CYBX), Edwards Lifescience (EW), Thoratec (THOR) and Volcano (VOLC) were all upgraded to Outperform from Neutral. Volcano was up 9% to 19 in late afternoon trading on 640k shares and is up about […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.